TDMS Study 88133-06 Pathology Tables
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 Final#2 Facility: Battelle Columbus Laboratory Chemical CAS #: 15625-89-5 Lock Date: 06/16/99 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include 002 0 MG/KG Include 001 0 MG/KG Include 004 0.75 MG/KG Include 003 0.75 MG/KG Include 006 1.5 MG/KG Include 005 1.5 MG/KG Include 008 3 MG/KG Include 007 3 MG/KG Include 010 6 MG/KG Include 009 6 MG/KG Include 012 12 MG/KG Include 011 12 MG/KG a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially In Study 15 15 15 15 15 15 Early Deaths Natural Death 1 2 1 1 3 Moribund Sacrifice 1 Survivors Terminal Sacrifice 15 14 12 14 14 12 Animals Examined Microscopically 15 15 15 15 15 15 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Liver (15) (15) (15) (15) (15) (15) Hematopoietic Cell Proliferation 1 (7%) 6 (40%) Infiltration Cellular 1 (7%) 1 (7%) Inflammation, Chronic Active 15 (100%) 14 (93%) 13 (87%) 13 (87%) 14 (93%) 8 (53%) Myelodysplasia 2 (13%) Pigmentation 12 (80%) 15 (100%) 12 (80%) 13 (87%) 14 (93%) 4 (27%) Hepatocyte, Necrosis 4 (27%) 2 (13%) 1 (7%) 2 (13%) 1 (7%) 1 (7%) Salivary Glands (1) (1) Parotid Gland, Infiltration Cellular 1 (100%) Tooth (1) (4) (3) (1) (3) (2) Fibrosis 1 (50%) Inflammation, Chronic Active 1 (100%) Malformation 1 (33%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (15) (15) (15) (15) (15) (15) Inflammation, Chronic Active 1 (7%) Atrium, Thrombosis 1 (7%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Pituitary Gland (15) (15) (15) (15) (15) (15) Pars Distalis, Angiectasis 1 (7%) Pars Distalis, Cyst 1 (7%) 2 (13%) 1 (7%) 2 (13%) 2 (13%) Thyroid Gland (15) (15) (15) (15) (15) (15) Infiltration Cellular 1 (7%) Inflammation, Chronic Active 2 (13%) a Number of animals examined microscopically at site and number of animals with lesion Page 2 NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (15) (15) (15) (15) (15) (15) Cyst 1 (7%) 1 (7%) 1 (7%) Inflammation, Chronic Active 1 (7%) 1 (7%) Pigmentation 1 (7%) 1 (7%) Uterus (15) (15) (15) (15) (15) (15) Hydrometra 1 (7%) 1 (7%) 1 (7%) 1 (7%) Inflammation, Chronic Active 1 (7%) Cervix, Inflammation, Chronic Active 1 (7%) Endometrium, Hyperplasia, Cystic 10 (67%) 11 (73%) 7 (47%) 8 (53%) 8 (53%) 9 (60%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Lymph Node (11) (14) (13) (10) (13) (12) Hematopoietic Cell Proliferation 2 (17%) Hyperplasia 2 (17%) Inguinal, Hematopoietic Cell Proliferation 1 (8%) Inguinal, Hyperplasia 1 (8%) Inguinal, Infiltration Cellular, Plasma Cell 2 (17%) Inguinal, Myelodysplasia 2 (17%) Mediastinal, Hematopoietic Cell Proliferation 5 (42%) Mediastinal, Infiltration Cellular 1 (8%) 2 (17%) Mediastinal, Infiltration Cellular, Plasma Cell 2 (17%) Lymph Node, Mandibular (15) (15) (15) (15) (15) (15) Hematopoietic Cell Proliferation 1 (7%) 6 (40%) Hyperplasia 1 (7%) 3 (20%) 2 (13%) 2 (13%) 3 (20%) Hyperplasia, Plasma Cell 1 (7%) 1 (7%) Infiltration Cellular 1 (7%) 1 (7%) Infiltration Cellular, Plasma Cell 1 (7%) 2 (13%) Inflammation, Chronic Active 1 (7%) Myelodysplasia 1 (7%) Lymph Node, Mesenteric (15) (14) (14) (15) (15) (15) Hematopoietic Cell Proliferation 4 (27%) Infiltration Cellular 2 (13%) Spleen (15) (15) (15) (15) (15) (15) a Number of animals examined microscopically at site and number of animals with lesion Page 3 NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - CONT Atrophy 1 (7%) 3 (20%) 1 (7%) 2 (13%) 1 (7%) Hematopoietic Cell Proliferation 7 (47%) 13 (87%) 9 (60%) 6 (40%) 8 (53%) 10 (67%) Hyperplasia, Lymphoid 2 (13%) 2 (13%) 2 (13%) Infiltration Cellular 1 (7%) Myelodysplasia 2 (13%) Thymus (15) (15) (15) (15) (15) (15) Atrophy 1 (7%) 3 (20%) 2 (13%) 2 (13%) 3 (20%) Thymocyte, Necrosis 2 (13%) 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (15) (15) (15) (15) (15) (15) Epidermis, Skin, Site of Application, Hyperplasia 1 (7%) 4 (27%) 15 (100%) 15 (100%) Epidermis, Skin, Site of Application, Hyperplasia, Focal 1 (7%) 1 (7%) 8 (53%) Skin, Site of Application, Hyperkeratosis 1 (7%) 7 (47%) 14 (93%) 13 (87%) Skin, Site of Application, Hyperplasia 1 (7%) Skin, Site of Application, Inflammation, Chronic Active 3 (20%) 14 (93%) 12 (80%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (15) (15) (15) (15) (15) (15) Inflammation, Chronic Active 1 (7%) Mediastinum, Infiltration Cellular 1 (7%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM None a Number of animals examined microscopically at site and number of animals with lesion Page 4 NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (15) (15) (15) (15) (15) (15) Inflammation, Chronic Active 2 (13%) 3 (20%) Mineralization 1 (7%) Nephropathy 4 (27%) 1 (7%) Renal Tubule, Cyst 1 (7%) Renal Tubule, Regeneration 1 (7%) 2 (13%) 1 (7%) a Number of animals examined microscopically at site and number of animals with lesion Page 5 NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially In Study 15 15 15 15 15 15 Early Deaths Natural Death 1 3 1 2 4 Survivors Terminal Sacrifice 14 15 12 14 13 11 Animals Examined Microscopically 15 15 15 15 15 15 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Liver (15) (15) (15) (15) (15) (15) Basophilic Focus 1 (7%) Hematopoietic Cell Proliferation 1 (7%) 1 (7%) 6 (40%) Infarct 1 (7%) Infiltration Cellular 5 (33%) Inflammation, Acute 1 (7%) Inflammation, Chronic Active 7 (47%) 10 (67%) 8 (53%) 8 (53%) 7 (47%) 8 (53%) Mineralization 1 (7%) Myelodysplasia 1 (7%) Pigmentation 2 (13%) Hepatocyte, Necrosis 2 (13%) 2 (13%) 2 (13%) 1 (7%) 1 (7%) Mesentery (1) (1) Fat, Necrosis 1 (100%) 1 (100%) Salivary Glands (1) (1) (2) Mandibular, Infiltration Cellular 1 (50%) Stomach, Forestomach (15) (15) (15) (15) (15) (15) Hyperkeratosis 1 (7%) 1 (7%) 3 (20%) Inflammation, Chronic Active 1 (7%) Epithelium, Hyperplasia 1 (7%) Tooth (1) (3) (1) (2) (1) (1) Inflammation, Chronic Active 1 (50%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (15) (15) (15) (15) (15) (15) Atrium, Thrombosis 1 (7%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM a Number of animals examined microscopically at site and number of animals with lesion Page 6 NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM - CONT Adrenal Cortex (15) (15) (15) (15) (15) (15) Hyperplasia 1 (7%) Hypertrophy 7 (47%) 5 (33%) 9 (60%) 8 (53%) 5 (33%) 5 (33%) Vacuolization Cytoplasmic 1 (7%) Pituitary Gland (15) (15) (15) (14) (15) (15) Pars Distalis, Cyst 2 (13%) 1 (7%) 1 (7%) 1 (7%) 1 (7%) 2 (13%) Thyroid Gland (15) (15) (15) (15) (15) (15) Inflammation, Chronic Active 1 (7%) Follicle, Cyst 1 (7%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (15) (15) (15) (15) (15) (15) Atrophy 1 (7%) Inflammation, Chronic Active 2 (13%) 3 (20%) Myelodysplasia 1 (7%) Bilateral, Hypospermia 1 (7%) Unilateral, Hypospermia 4 (27%) 3 (20%) 1 (7%) 1 (7%) 2 (13%) Preputial Gland (1) (1) Inflammation, Chronic Active 1 (100%) Duct, Ectasia 1 (100%) Testes (15) (15) (15) (15) (15) (15) Cyst 2 (13%) 1 (7%) 1 (7%) Bilateral, Germinal Epithelium, Degeneration 1 (7%) Germinal Epithelium, Degeneration 1 (7%) Unilateral, Germinal Epithelium, Degeneration 4 (27%) 3 (20%) 1 (7%) 1 (7%) 2 (13%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Lymph Node (13) (13) (14) (15) (14) (14) Hyperplasia 4 (29%) Inflammation, Chronic Active 3 (21%) Axillary, Infiltration Cellular 1 (7%) Axillary, Infiltration Cellular, Plasma Cell 1 (7%) Inguinal, Hyperplasia 1 (7%) Inguinal, Inflammation, Chronic Active 1 (7%) a Number of animals examined microscopically at site and number of animals with lesion Page 7 NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - CONT Mediastinal, Hematopoietic Cell Proliferation 1 (7%) Mediastinal, Hyperplasia 1 (7%) Mediastinal, Infiltration Cellular 3 (21%) Mediastinal, Infiltration Cellular, Plasma Cell 3 (21%) Mediastinal, Inflammation, Chronic Active 2 (14%) Lymph Node, Mandibular (15) (14) (15) (15) (14) (13) Hematopoietic Cell Proliferation 2 (15%) Hyperplasia 1 (7%) 1 (8%) Hyperplasia, Plasma Cell 1 (7%) 1 (7%) Infiltration Cellular 4 (31%) Infiltration Cellular, Plasma Cell 1 (8%) Lymph Node, Mesenteric (15) (14) (14) (15) (15) (12) Infiltration Cellular 1 (8%) Spleen (15) (15) (15) (15) (15) (15) Atrophy 1 (7%) 1 (7%) 4 (27%) Depletion Cellular 1 (7%) 1 (7%) Hematopoietic Cell Proliferation 1 (7%) 4 (27%) 1 (7%) 2 (13%) 6 (40%) 8 (53%) Hyperplasia, Lymphoid 1 (7%) 1 (7%) 1 (7%) 1 (7%) Thymus (15) (15) (14) (15) (15) (15) Atrophy 1 (7%) 1 (7%) 2 (13%) 5 (33%) Thymocyte, Necrosis 1 (7%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (15) (15) (15) (15) (15) (15) Epidermis, Skin, Site of Application, Hyperplasia 6 (40%) 14 (93%) 15 (100%) Epidermis, Skin, Site of Application, Hyperplasia, Focal 1 (7%) 1 (7%) Skin, Site of Application, Hyperkeratosis 1 (7%) 15 (100%) 14 (93%) 12 (80%) Skin, Site of Application, Hyperplasia 1 (7%) Skin, Site of Application, Inflammation, Chronic Active 1 (7%) 1 (7%) 9 (60%) 12 (80%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM a Number of animals examined microscopically at site and number of animals with lesion Page 8 NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02 Route: SKIN APPLICATION Time: 08:48:56 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (15) (15) (15) (15) (15) (14) Inflammation, Chronic Active 2 (13%) 2 (14%) Thrombosis 1 (7%) Interstitium, Hyperplasia 1 (7%) Interstitium, Inflammation, Chronic Active 1 (7%) Mediastinum, Infiltration Cellular 1 (7%) Mediastinum, Inflammation, Chronic Active 1 (7%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM None ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (15) (15) (15) (15) (15) (15) Infarct 1 (7%) 1 (7%) Infiltration Cellular 1 (7%) Infiltration Cellular, Mononuclear Cell 1 (7%) 1 (7%) 1 (7%) Inflammation, Chronic Active 2 (13%) 1 (7%) 1 (7%) 5 (33%) Mineralization 1 (7%) Nephropathy 3 (20%) 6 (40%) 3 (20%) Glomerulus, Renal Tubule, Dilatation 1 (7%) Renal Tubule, Cyst 1 (7%) 1 (7%) 1 (7%) Renal Tubule, Hyperplasia 1 (7%) 1 (7%) 1 (7%) 1 (7%) Renal Tubule, Regeneration 2 (13%) 1 (7%) 5 (33%) 4 (27%) 4 (27%) a Number of animals examined microscopically at site and number of animals with lesion Page 9 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------